Peeling Back The Layers: Exploring Xencor Through Analyst Insights
In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 2 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $35.4, a high estimate of $40.00, and a low estimate of $31.00. A decline of 17.29% from the prior average price target is evident in the current average.
Investigating Analyst Ratings: An Elaborate Study
A clear picture of Xencor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sean McCutcheon | Raymond James | Lowers | Strong Buy | $40.00 | $58.00 |
| Etzer Darout | BMO Capital | Lowers | Outperform | $32.00 | $34.00 |
| Gregory Renza | RBC Capital | Lowers | Outperform | $31.00 | $32.00 |
| David Nierengarten | Wedbush | Raises | Outperform | $36.00 | $34.00 |
| Kaveri Pohlman | BTIG | Lowers | Buy | $38.00 | $56.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xencor. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xencor compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Xencor's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Xencor's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Xencor analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Xencor
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Xencor: Delving into Financials
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Xencor's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -32.47%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Xencor's net margin is impressive, surpassing industry averages. With a net margin of -531.3%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Xencor's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -10.62%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Xencor's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.41%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Xencor's debt-to-equity ratio is below the industry average. With a ratio of 0.15, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.